Industry’s Rebate Arms Race: Securing Market Access At A Cost
Executive Summary
Rebates have become industry’s go-to for securing market access for drugs in competitive therapeutic areas in the US. But as payers push back, competitive rebating is intensifying and eating into the bottom line.
You may also be interested in...
Drug Pricing: PhRMA Report Aims To Shift Focus To Supply Chain
More than one-third of gross sales for brands is eaten up by rebates, discounts and fees, a study finds, raising questions about whether price concessions provided to payers are ‘flowing to patients,’ PhRMA President Stephen Ubl says.
Oncology Booming But Cost Outlook Grim, IMS Says
The cost of oncology therapeutics and supportive care drugs grew 11.5% to $107bn in 2015 at constant exchange rates and is expected to reach $150bn globally in 2020, according to a new report.
Express Scripts Tightens Commercial Formulary Control With “Not Covered” List
The excluded drug list encompasses 44 drugs across a range of classes and applies to Express Scripts’ 2014 recommended national formulary for employers and health plans.